RJA
BIIB icon

Ross\Johnson & Associates’s Biogen BIIB Stock Holding History

Ross\Johnson & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216 Hold
1
– – ﹤0.01% 220
2026
Q1 		$183 Hold
1
– – ﹤0.01% 178
2025
Q4 		$176 Hold
1
– – ﹤0.01% 259
2025
Q3 		$140 Hold
1
– – ﹤0.01% 192
2025
Q2 		$126 Hold
1
– – ﹤0.01% 192
2025
Q1 		$136 Buy
+1
New +$143 ﹤0.01% 335

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ross\Johnson & Associates's BIIB Position: Q2 2026 in Review

Ross\Johnson & Associates held its Biogen (BIIB) position steady in Q2 2026 at 1 share worth $216. The position accounts for ﹤0.01% of the portfolio, ranked #220.

Ross\Johnson & Associates first reported a position in BIIB in Q1 2025 and has held it in 6 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Ross\Johnson & Associates held 1 share of Biogen worth $216 as of Q2 2026.
  • Ross\Johnson & Associates left its Biogen share count unchanged in Q2 2026.
  • Biogen made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #220 holding.
  • Ross\Johnson & Associates first reported a position in Biogen in Q1 2025 and has held it in 6 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.